GlaxoSmithKline Pharmaceuticals Share Price | GlaxoSmithKline Pharmaceuticals Stock Screener
GLAXO
Pharmaceuticals
Share Price NSE
₹2296.20
▲
13.80 (0.60%)
Share Price BSE
₹2301.05
▲
17.90 (0.78%)
As of May 27, 2026, the GlaxoSmithKline Pharmaceuticals share price (NSE: GLAXO) is ₹2,296.20 on NSE and ₹2,301.05 on BSE, up 0.60% from the previous close, with shares trading between ₹2,283.20 and ₹2,315.90, and a 52-week range of ₹2,259.50–₹3,466.20.
Check GlaxoSmithKline Pharmaceutical yearly highs lows for the annual price range and momentum.
Use the GlaxoSmithKline Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
GlaxoSmithKline Pharmaceuticals Market Cap
₹38,899.01 Cr.
GLAXO P/E Ratio (TTM)
37.34
GlaxoSmithKline Pharmaceuticals P/B Ratio
17.06
EPS (TTM)
₹60.11
Dividend Yield
2.50%
Debt to Equity
0.01
GLAXO 52 Week High
₹3466.20
GlaxoSmithKline Pharmaceuticals 52 Week Low
₹2259.50
Operating Margin
35.00%
Profit Margin
26.96%
GLAXO Revenue (TTM)
₹1,031.00
EBITDA
₹387.00
Net Income
₹278.00
Total Assets
₹4,324.00
Total Equity
₹2,267.00
GlaxoSmithKline Pharmaceuticals Share Price Chart
Screen GlaxoSmithKline Pharmaceuticals share price with an interactive chart. Analyse GLAXO price trends and volatility across different timeframes.
GlaxoSmithKline Pharmaceuticals Company Profile - Fundamental Screener
Screen GlaxoSmithKline Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GLAXO shares.
GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Renu S Karnad
ISIN
INE159A01016
Website
https://www.gsk-india.com
GlaxoSmithKline Pharmaceuticals Balance Sheet Screener
Screen GLAXO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 4,324 | 4,108 | 3,557 | 3,327 | 4,633 | 3,115 | 3,136 | 3,911 | 3,948 | 3,004 |
| Current Assets | 3,606 | 3,410 | 2,798 | 2,494 | 3,708 | 2,203 | 1,775 | 2,010 | 2,186 | 1,674 |
| Fixed Assets | 314 | 284 | 321 | 330 | 331 | 387 | 758 | 432 | 325 | 258 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 277 | 252 | 254 | 259 | 272 | 282 | 291 | 317 | 290 | 277 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 2,267 | 1,951 | 1,778 | 1,741 | 2,663 | 1,478 | 1,821 | 2,140 | 2,057 | 2,007 |
| Share Capital | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 85 | 85 |
| Reserves & Surplus | 2,098 | 1,782 | 1,608 | 1,572 | 2,494 | 1,309 | 1,651 | 1,970 | 1,973 | 1,922 |
GlaxoSmithKline Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen GlaxoSmithKline Pharmaceuticals income statement and profit fundamentals.
Analyze GLAXO quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for GlaxoSmithKline Pharmaceuticals share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,031 | 1,091 | 1,016 | 849 | 1,015 | 985 | 1,050 | 850 | 962 | 833 | 985 | 815 | 826 | 826 | 939 |
| Expenses | 644 | 670 | 644 | 554 | 641 | 658 | 689 | 584 | 673 | 751 | 668 | 618 | 618 | 585 | 660 |
| EBITDA | 387 | 421 | 372 | 295 | 374 | 327 | 361 | 266 | 290 | 83 | 318 | 198 | 208 | 241 | 279 |
| Operating Profit % | 35.00% | 36.00% | 34.00% | 31.00% | 34.00% | 31.00% | 32.00% | 28.00% | 28.00% | 7.00% | 30.00% | 19.00% | 22.00% | 27.00% | 28.00% |
| Depreciation | 13 | 20 | 17 | 16 | 15 | 19 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 16 | 16 |
| Interest | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit Before Tax | 373 | 400 | 354 | 279 | 359 | 308 | 344 | 249 | 271 | 65 | 299 | 181 | 190 | 224 | 262 |
| Tax | 95 | 104 | 97 | 74 | 96 | 78 | 91 | 67 | 76 | 20 | 82 | 49 | 57 | 60 | 69 |
| Net Profit | 278 | 296 | 258 | 205 | 263 | 230 | 253 | 182 | 195 | 46 | 218 | 132 | 133 | 165 | 193 |
| EPS | 16.40 | 16.54 | 15.07 | 12.10 | 15.52 | 13.57 | 14.67 | 10.76 | 11.37 | 9.89 | 12.84 | 7.04 | 7.41 | 9.71 | 11.42 |
GlaxoSmithKline Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen GLAXO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,290 | 582 | 484 | 811 | 578 | 491 | 410 | 473 | 234 | 139 |
| Investing Activities | -46 | 9 | 808 | -406 | 418 | -57 | -153 | -104 | 301 | 499 |
| Financing Activities | -769 | -562 | -1,543 | -524 | -696 | -428 | -358 | -307 | -511 | -638 |
| Net Cash Flow | 475 | 29 | -251 | -119 | 300 | 6 | -102 | 62 | 24 | 0 |
GlaxoSmithKline Pharmaceuticals Shareholding Pattern Screener
See GlaxoSmithKline Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check GlaxoSmithKline Pharmaceuticals promoter holding and ownership changes for GLAXO on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII Holding | 4.62% | 4.52% | 4.89% | 4.80% | 4.64% | 3.48% | 4.02% | 4.36% |
| DII Holding | 7.68% | 7.79% | 7.70% | 7.75% | 7.70% | 7.90% | 7.50% | 7.34% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 10.35% | 10.60% | 10.32% | 10.34% | 10.36% | 11.27% | 11.15% | 10.97% |
| Other Holding | 2.35% | 2.09% | 2.09% | 2.11% | 2.30% | 2.35% | 2.33% | 2.33% |
| Shareholder Count | 121,763 | 121,885 | 123,629 | 122,904 | 122,460 | 118,994 | 118,515 | 119,228 |
GlaxoSmithKline Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check GlaxoSmithKline Pharmaceuticals dividend history with payout and yield data.
View GlaxoSmithKline Pharmaceuticals dividend details including ex-dates and amounts for GLAXO stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹54.00 | 2.37% |
| 2024-March | ₹32.00 | 1.11% |
| 2023-March | ₹32.00 | 1.64% |
| 2022-March | ₹90.00 | 7.05% |
| 2021-March | ₹30.00 | 1.80% |
| 2020-March | ₹40.00 | 2.78% |
| 2019-March | ₹20.00 | 1.59% |
| 2018-March | ₹35.00 | 2.70% |
| 2017-March | ₹30.00 | 2.87% |
GlaxoSmithKline Pharmaceuticals Stock Index Membership
See which indices include GlaxoSmithKline Pharmaceuticals stock.
Check GLAXO index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEQUI
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 500
NIFTY LARGEMID250
NIFTY M150 QLTY50
NIFTY MIDCAP 150
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
GlaxoSmithKline Pharmaceuticals Market Events Screener - Corporate Actions
Get GlaxoSmithKline Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check GlaxoSmithKline Pharmaceuticals stock events that may affect GLAXO share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Bonus | 1:1 | -0.11% | ||
| 2026-06-30 | 2026-06-30 | Annual General Meeting | NA | -6.80% |
| 2026-05-29 | 2026-05-29 | Dividend | ₹ 57.00 /share | -6.80% |
| 2026-05-13 | 2026-05-13 | Quarterly Result Announcement | NA | 0.88% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 1.10% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -3.50% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | -3.21% |
| 2025-06-27 | 2025-06-27 | Annual General Meeting | NA | 21.34% |
| 2025-05-30 | 2025-05-30 | Dividend | ₹ 42.00 /share | 19.92% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | -7.08% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -3.77% |
| 2024-11-07 | 2024-11-07 | Dividend | ₹ 12.00 /share | -0.47% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | 0.52% |
| 2024-06-28 | 2024-06-28 | Annual General Meeting | NA | 32.30% |
| 2024-05-31 | 2024-05-31 | Dividend | ₹ 32.00 /share | 28.12% |
GlaxoSmithKline Pharmaceuticals Competitors Screener - Peer Comparison
Screen GLAXO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 442,509 | 38.37 | 58,220 | 6.38% | 11,565 | 54.66 |
| Divis Laboratories | 180,452 | 69.82 | 10,560 | 8.73% | 2,520 | 59.28 |
| Torrent Pharmaceuticals | 153,580 | 70.46 | 13,753 | 19.18% | 2,028 | 60.91 |
| Cipla | 114,559 | 29.64 | 27,712 | -2.46% | 3,783 | 64.86 |
| Dr Reddys Laboratories | 110,089 | 26.69 | 33,593 | -0.44% | 3,998 | 54.22 |
| Zydus Life Science | 109,257 | 21.19 | 26,720 | 13.65% | 5,242 | 75.42 |
| Lupin | 104,041 | 19.33 | 27,488 | 19.98% | 5,345 | 46.91 |
| Mankind Pharma | 99,915 | 51.52 | 14,278 | 12.03% | 1,750 | 55.29 |
| Aurobindo Pharma | 83,397 | 24.27 | 33,385 | 3.21% | 3,376 | 47.24 |
| Laurus Labs | 74,592 | 83.31 | 6,813 | 21.03% | 884 | 80.70 |
GlaxoSmithKline Pharmaceuticals Company Announcements - News Screener
Screen GLAXO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-28 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-13 | Corporate Action-Board approves Dividend | - |
| 2026-05-13 | Record Date For Final Dividend 29Th May 2026 | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Dividend Updates | - |
| 2026-05-13 | AGM | - |
| 2026-05-13 | Corporate Action-Board approves Dividend | - |
| 2026-05-13 | Outcome Of Meeting | - |
| 2026-05-13 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-05-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-04-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-22 | Board Meeting Intimation for Audited Financial Results (Standalone & Consolidated) For The Year Ended 31St March 2026 And Dividend If Any | - |
| 2026-04-21 | Disclosure Under Regulation 30(5) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 | - |
| 2026-04-21 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-08 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |